Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of October 2020, with a report date of October 7, 2020. The filing announces the implementation of a shareholder-approved reverse stock split and a corresponding adjustment to the American Depositary Share (ADS) ratio.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions regarding share structure rather than financial performance.
Material Changes
- Reverse Split: Shareholders approved a reverse split of ordinary shares by a ratio of up to 20:1.
- ADS Ratio Change: The ratio of ordinary shares underlying each ADS will change from 40 pre-split shares to 140 post-split shares.
- Par Value Adjustment: The par value of ordinary shares will increase from NIS 0.01 to NIS 0.20 per share.
- Effective Dates: The changes become effective at the close of business on October 16, 2020. Trading on a post-split basis on the OTC Markets (Pink Open Market) under symbol "TRPXY" begins October 19, 2020.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the structural changes to the share capital. The primary contingency noted is the successful implementation of the reverse split and ratio change on the specified dates.
Investor Verification Checklist
- Verify the exact reverse split ratio implemented (up to 20:1) and confirm the final post-split share count.
- Confirm the new ADS ratio of 140 ordinary shares per ADS is reflected in brokerage accounts.
- Check trading activity on the OTC Markets under symbol "TRPXY" starting October 19, 2020.
- Review the amended Articles of Association to confirm the new par value of NIS 0.20.